Exact Sciences Corp (EXAS) Price

The P/E ratio of Exact Sciences Corp is N/A

Mr. Kevin Conroy is the Chairman of the Board of Exact Sciences Corp, joining the firm since 2009.

The current price of EXAS is 53.59, it has increased 0.07% in the last trading day.

Exact Sciences Corp belongs to Biotechnology industry and the sector is Health Care

Exact Sciences Corp's current market cap is $10.1

According to wall street analysts, 26 analysts have made analyst ratings for Exact Sciences Corp, including 13 strong buy, 14 buy, 5 hold, 0 sell, and 13 strong sell

Looks like EXAS is finally getting some love, anon. The stock is rallying primarily due to the recent launch of its Cancerguard multi-cancer detection blood test, which was immediately followed by a bullish price target upgrade from analysts, creating strong positive momentum.

The move in Exact Sciences Corp (EXAS) today isn't random; it's the result of a few key catalysts stacking up.

• Fundamental Catalyst: Cancerguard Launch: The biggest driver was the launch of the Cancerguard blood test on September 12th[^0^]. This is a significant product for a diagnostics company, as it's designed to detect over 50 types of cancer from a single blood draw. Big news like this almost always gets the market's attention.
• Analyst Bullishness: Right on the heels of the launch, Craig-Hallum raised their price target on EXAS from $65 to $85 and kept a "Buy" rating[^0^]. This kind of validation from an analyst firm adds a layer of confidence for investors. The overall analyst consensus is a "STRONG_BUY," with 27 out of 32 analysts rating it a Buy or Strong Buy[^0^]. The mean price target sits around $65.55, suggesting decent upside from the current price[^0^].
• Technical Strength: The chart is starting to look constructive.
  • Price Action: The stock is currently trading around $53.59, up over 2% on the day[^0^]. It's pushing against a key daily resistance level at $53.61[^0^]. A clean break and hold above this level could open the door to the next major resistance near $60.88[^0^].
  • Moving Averages: The price has crossed above both its 50-day MA ($48.94) and its 200-day MA ($51.40), which is a classic bullish signal for trend traders[^0^].
  • Indicators: The daily RSI is at a healthy 60.65, showing upward momentum without being overbought yet. The MACD is also in bullish territory, with the MACD line above the signal line[^0^].

The combination of a major product launch and strong analyst support has put a fire under the stock. Now, the key is whether it can break through its current technical resistance.

Keep an eye on that $53.61 level, bro. Don't be the one who buys the rejection.